Pub. Date : 2015 May
PMID : 25805645
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The objective of the present study was to determine whether genetic variants of the dopamine transporter type 1-encoding gene (SLC6A3) are associated with differences in the response to treatment of motor symptoms and gait disorders with l-DOPA and methylphenidate (with respect to the demographic, the disease and the treatment parameters and the other genes involved in the dopaminergic neurotransmission). | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 2 | The SLC6A3 variants were significantly associated with greater efficacy of l-DOPA for motor symptoms. | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 3 | The SLC6A3 variants were also associated with greater efficacy of methylphenidate for motor symptoms and gait disorders in the ON l-DOPA condition. | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 4 | Our preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson"s disease. | Levodopa | solute carrier family 6 member 3 | Homo sapiens |